Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is it reasonable to use hypofractionation in breast cancer patients with non-active connective tissue disorders?
Answer from: Radiation Oncologist at Academic Institution
Yes, it is reasonable to use hypofractionation in this patient panel. I have used the Canadian fractionation schedule several times in this scenario.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I’ve also routinely done this with no issue at all.
Sign in or Register to read more
15771
15793
Related Questions
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
When treating early stage breast cancer with adjuvant RT, what risk factors would lead you to include the level 1 and 2 axilla in patients with pN0(i+) disease?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
When using FAST Forward, how important is it for the treatment to be delivered Monday through Friday in one week as opposed to spanning a weekend?
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?
Do you consider chest wall constraints when treating with 5-fraction APBI?